For supply chain security, ‘don’t live in the moment’ - CPHI Frankfurt preview
CPHI caught up with Jim Fries to discuss sustainable supply chains ahead of his CPHI Frankfurt panel discussion
At the core of the pharmaceutical industry is the mission to provide patients with safe, high-quality drugs when they need them. To do this, pharma companies must ensure the timely delivery of their drugs to a potentially global customer base, which requires secure supply chains and a sustainable approach to business.
This will be the subject of the presentation Sustainability, Quality and Supply Chain Integrity: A New View at CPHI Frankfurt this year. In this session, CEO of the nonprofit international consortium Rx-360, Jim Fries will discuss the intersection of sustainability, quality, and supply chain integrity in the post-pandemic era and explore how best practices in one sector can lead to positive changes in the others.
Jim’s session will take place on November 2 – Register for CPHI Frankfurt now.
Jim Fries, Chief Executive Officer, Rx-360
You will be presenting the session Sustainability, Quality and Supply Chain Integrity at CPHI Frankfurt. What can attendees expect to gain from this session?
They will gain a great understanding of how these areas link together. It will leave them thinking about how they can improve in these areas. Every company and organisation is different, my goal is to get them thinking with value points and queries.
The pandemic shone a light on issues in the supply chain and prompted a mass re-evaluation of how to prevent shortages. What advice can you give for promoting supply chain resilience?
Have multiple suppliers and always think ahead. Don’t live in the moment
Why are you attending CPHI Frankfurt this year?
Great opportunity to interact with international colleagues and support the mission of Rx-360 as an international consortium.
We have a packed agenda of content and networking opportunities at this year’s event. What are you most looking forward to?
To be honest, the networking opportunities.
CPHI’s new brand line is ‘At the heart of Pharma’. What does that mean to you?
Understanding what is going on at the root level. Dive deep!
Related News
-
News A Day in the Life of a Vice President of Business Development
In this month's Day in the Life Of interview, I spoke to Nigel Stapleton, VP of Business Development in Biopharmaceutical Contract Manufacturing for Mabion SA, about his illustrious career and some personal highlights. -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
-
News Women in Pharma: Building from the ground up together
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pharmaceutical Packaging Market Prospects – Innovations in Packaging and Drug Delivery
Download the Pharmaceutical Packaging Market Prospects Trend Report to explore the full report and delve into the evolving opportunities in pharmaceutical packaging and drug delivery. -
News Novartis to invest US$23 billion in US facilities amid tariff threats
Swiss pharmaceutical giant Novartis has announced its intention to invest up to US$23 billion in building and expanding ten pharmaceutical facilities in the US as drugmakers scramble to respond to potential drug import and manufacturing tariffs declare... -
News CPHI Podcast Series: Fulfilling an unmet need for rare disease patients
Our April episode from the CPHI Podcast Series is looking into rare diseases, and more specifically how pharmaceutical companies can better support this smaller population of rare disease patients.